Y-mAbs Therapeutics (YMAB) to Release Quarterly Earnings on Tuesday

Y-mAbs Therapeutics (NASDAQ:YMAB) is expected to be releasing its earnings data before the market opens on Tuesday, March 4th. Analysts expect Y-mAbs Therapeutics to post earnings of ($0.13) per share and revenue of $26.70 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ YMAB opened at $5.69 on Tuesday. Y-mAbs Therapeutics has a 1 year low of $5.47 and a 1 year high of $20.90. The firm has a 50-day moving average of $6.84 and a 200 day moving average of $10.87. The stock has a market cap of $254.85 million, a P/E ratio of -10.54 and a beta of 0.67.

Analyst Ratings Changes

YMAB has been the topic of several recent analyst reports. Brookline Capital Management initiated coverage on Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. Wedbush restated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Friday, January 10th. Finally, Oppenheimer started coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price for the company. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $20.89.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.